CAS 1599440-33-1

DX-8951 derivative

Description:

DX-8951 derivative, identified by its CAS number 1599440-33-1, is a synthetic compound that belongs to a class of molecules known for their potential therapeutic applications, particularly in the field of oncology. This compound is characterized by its specific molecular structure, which includes various functional groups that contribute to its biological activity. Typically, derivatives like DX-8951 are designed to enhance efficacy, reduce toxicity, or improve pharmacokinetic properties compared to their parent compounds. The substance may exhibit properties such as selective inhibition of certain enzymes or pathways involved in cancer cell proliferation, making it a candidate for targeted therapy. Additionally, its solubility, stability, and interaction with biological systems are crucial for its development as a pharmaceutical agent. Research into DX-8951 derivative may involve in vitro and in vivo studies to assess its safety, effectiveness, and mechanism of action, contributing to the broader understanding of its potential role in cancer treatment.

Formula: C₂₆H₂₄FN₃O₆

Dxd

CAS: 1599440-33-1

Formula: C₂₆H₂₄FN₃O₆

Purity: 98%

Color and Shape: Solid

Molecular weight: 493.4837

Ref: IN-DA01EOPD

Dxd

CAS: 1599440-33-1

Dxd

Purity: ≥95%

Molecular weight: 493.48g/mol

Ref: 54-BUP09182

Dxd

CAS: 1599440-33-1

Dxd (OQM5SD32BQ) is a potent DNA topoisomerase I inhibitor (IC50= 0.31 μM). Dxd was used as a conjugate drug for HER2-targeted ADCs. High-Quality, Low-Cost!

Formula: C₂₆H₂₄FN₃O₆

Purity: 98.21% - ≥98%

Color and Shape: Solid

Molecular weight: 493.48

Ref: TM-T11249L

N-((1S,9S)-9-Ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3′,4′:6,7]indolizino[1,2-b]quinolin-1-yl)-2-hydroxyacetamide

CAS: 1599440-33-1

Purity: 98%

Molecular weight: 493.491

Ref: 10-F982466

Dxd

CAS: 1599440-33-1

Dxd is a type of Antibody-Drug Conjugate (ADC), which is a sophisticated therapeutic agent arising from bioconjugate chemistry. It incorporates a monoclonal antibody that specifically targets cancer cell antigens, linked to a cytotoxic payload designed to induce cell death. The mechanism of action involves the highly selective binding of the ADC to a cancer-specific antigen, followed by internalization, and subsequent release of the cytotoxic agent within the cell. This targeted approach allows for the preferential destruction of cancer cells while minimizing damage to healthy tissues.

Formula: C₂₆H₂₄FN₃O₆

Purity: Min. 95%

Molecular weight: 493.5 g/mol

Ref: 3D-ZNC44033